Get the latest delivered to your inbox
Privacy Policy

Now Reading

Elanco CEO, Jeff Simmons Launches Mission to Save 1 Million Puppies from Deadly Parvo

Elanco CEO, Jeff Simmons Launches Mission to Save 1 Million Puppies from Deadly Parvo

Published 02-08-24

Submitted by Elanco Foundation

Jeff Simmons, President and CEO of Elanco Animal Health, joined Jim Cramer on Mad Money to discuss Elanco’s exciting pipeline with six potential blockbuster products expected to launch in major markets over the next two years. The company recently launched the first and only USDA conditionally-approved therapeutic solution proven to treat canine parvovirus (parvo) — one of the most contagious and deadly viruses a dog can contract with a 91%1 mortality rate if not treated with supportive care.

In support of this cause, Elanco announced a first-of-its-kind, multi-year campaign to save 1 million puppies from unnecessary death from the highly contagious parvo: Defend Puppies. Defeat Parvo.  An estimated 900 dogs are diagnosed with parvo daily2 in the U.S. – mostly unvaccinated puppies. Yet Elanco research revealed only 44% of dog owners know what parvo is, with 20% having no knowledge of the disease.3 With dog owners being the first line of defense in protecting their puppies, there is need for more wide-spread education.  

With the introduction of the Defend Puppies. Defeat Parvo. mission, Elanco aims to increase education about this deadly disease, while increasing veterinarian’s access to the first and only U.S. Department of Agriculture (USDA) conditionally approved treatment for parvo – Elanco’s Canine Parvovirus Monoclonal Antibody.

1 Sykes, JE. Canine Parvovirus Infections and Other Viral Enteritides. Canine and Feline Infectious Diseases. 2014:141-151
2 Elanco Animal Health. Data on File.
3 Elanco Animal Health. Market Data on File.

Elanco Foundation logo

Elanco Foundation

Elanco Foundation

Elanco is a global innovation-driven company that develops and markets products to improve animal health and food animal production in more than 75 countries. Elanco employs more than 2,400 people worldwide, with offices in more than 40 countries, and is a division of Eli Lilly and Company, a leading global pharmaceutical corporation. Additional information about Elanco is available at

More from Elanco Foundation

Join today and get the latest delivered to your inbox